Marker Therapeutics Inc. (MRKR)
MRKR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1094038/000110465926031274/0001104659-26-031274-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | MRKR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001094038 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $3.5M |
| Net income | -$12.2M |
| Operating income | -$12.9M |
| Net margin | -343.0% |
| Operating margin | -363.5% |
| Revenue growth | -46.2% |
| Cash | $16.1M |
| Total assets | $19.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 3.9× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors raise substantial doubt regarding the Company's ability to continue as a going concern." | 10-Q 2026-08-14 |
| Cash and burn | $11.3M cash; operating cash flow -$2.4M a quarter. | Report 2026-06-30 |
| Shares outstanding | 16,673,127 (2026-08-07); 12,938,910 a year earlier; 8,809,260 three years earlier. | Cover page 2026-08-07 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | CBIZ CPAs P.C., Houston, Texas, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-08-12 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$1.8M | -$3.7M | $11.3M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | $752K | -$3.2M | -$1.4M | $14.9M | No debt tags | $3.9M | 10-Q 2026-05-15 |
| Q4 2025 2025-12-31 | $1.1M | -$1.7M | -$1.9M | $16.1M | No debt tags | $3.5M | 10-K 2026-03-18 |
| Q3 2025 2025-09-30 | $1.2M | -$2.0M | -$2.7M | $17.6M | No debt tags | $4.7M | 10-Q 2025-11-13 |
| Q2 2025 2025-06-30 | $861K | -$4.0M | -$1.9M | $10.5M | No debt tags | $5.4M | 10-Q 2025-08-14 |
| Q1 2025 2025-03-31 | $349K | -$4.4M | -$5.5M | $13.7M | No debt tags | $5.7M | 10-Q 2026-05-15 |
| Q4 2024 2024-12-31 | $2.3M | -$3.8M | -$4.7M | $19.2M | No debt tags | $6.6M | 10-K 2026-03-18 |
| Q3 2024 2024-09-30 | $1.9M | -$2.3M | $1.2M | $9.0M | No debt tags | $5.4M | 10-Q 2025-11-13 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B7 | 2025-08-05 |
| Latest annual report | 10-K | 2026-03-18 |
| Latest quarterly / interim | 10-Q | 2026-11-16 |
| Latest current report FORM 8-K | 8-K | 2026-10-19 |
| Latest proxy | DEFA14A | 2026-03-20 |
Source: SEC EDGAR submissions feed, 905 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -2.2% |
| 1 month | -5.4% |
| 3 months | -21.6% |
| Year to date | -41.6% |
| 1 year | -2.2% |
| From 52-week high | -60.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ALLR | Allarity Therapeutics Inc. | $0.8752 | -8.24% | $13.9M |
| NEUP | Neuphoria Therapeutics Inc. | $2.48 | -2.75% | $13.4M |
| MCRB | Seres Therapeutics Inc. | $1.41 | +0.71% | $14.4M |
| CTXR | Citius Pharmaceuticals Inc. | $0.5276 | -1.40% | $14.5M |
| CMMB | Chemomab Therapeutics Ltd. American Depositary Share | $1.62 | +5.88% | $13.0M |
| TVRD | Tvardi Therapeutics Inc. | $1.10 | -6.78% | $14.7M |
| KYNB | Kyntra Bio Inc. | $3.20 | -8.31% | $13.0M |
| ACTU | Actuate Therapeutics Inc. | $0.2680 | -7.59% | $14.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier